Treating the brain cancer glioblastoma (GBM) demands more than conventional strategies due to a mix of factors including the cancer’s genetic complexity, invasive growth, and immune resistance. A new ...

Clinical effectiveness of immune therapies of solid tumors requires a) the induction or expansion of T cells able of recognizing multiple variants of cancer cells present in each cancer patient, and b ...

Bria-IMT demonstrates a median overall survival of 15.6 months, surpassing historical data for heavily pretreated metastatic ...

Overview of the manufacturing process of personalized neoantigen-based DC vaccines. A typical basic process of manufacturing neoantigen-based DC vaccines by using monocyte-derived dendritic cells is ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

An international research team with strong participation from DTU has developed a new biotechnological platform that makes it possible to test and understand advanced cancer treatments much faster and ...